

OMB No. 0651-0011 (12/31/86)

Applicant or Patentee: Michael HERSHFIELD and Susan J. KELLY Attorney's Dkt. No. 1579-527
Serial or Patent No.: _____
Filed or Issued: _____
For: URATE OXIDASE

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS [37 19(f) and 1.27(c)] - SMALL BUSINESS CONCERN**

I hereby declare that I am

☐
☒

the owner of the small business concern identified below:

an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN Bio-Technology General (Israel) Ltd. Corporation

ADDRESS OF CONCERN 76326 Rehovot, ISRAEL- 70 Wood Avenue South, Iselin, NJ 08830

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled:

URATE OXIDASE

by inventors Michael HERSHFIELD and Susan J. KELLY described in

☐ the specification filed herewith.

☐ application Serial No. _____, filed _____

☐ patent No. _____, issued _____

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor who could not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e). *NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities (37 CFR 1.27)

Name _____

Address _____

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

Name _____

Address _____

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

I acknowledge the duty to file, in this application of patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. [37 CFR 1.28(b)]

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING

TITLE OF PERSON OTHER THAN OWNER

ADDRESS OF PERSON SIGNING

SIGNATURE

Robert M. Shaw

Sen. Vice President

70 Wood Avenue South, Iselin, NJ 08830

DATE

Jan 23, 2001

SEQUENCE LISTING

<110> HERSHFIELD, MICHAEL S.
KELLY, SUSAN J.

<120> URATE OXIDASE

<130> 1579-267

<140>

<141>

<160>11

<170> PatentIn Ver. 2.0

<210> 1

<211> 915

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (1)..(915)

<220>

<223> Description of Artificial Sequence:PBC CHIMERA

<400> 1

atg gct cat tac cgt aat gac tac aaa aag aat gat gag gta gag ttt	48
Met Ala His Tyr Arg Asn Asp Tyr Lys Lys Asn Asp Glu Val Glu Phe	
1 5 10 15	
gtc cga act ggc tat ggg aag gat atg ata aaa gtt ctc cat att cag	96
Val Arg Thr Gly Tyr Gly Lys Asp Met Ile Lys Val Leu His Ile Gln	
20 25 30	
cga gat gga aaa tat cac agc att aaa gag gtg gca act tca gtg caa	144
Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln	
35 40 45	
ctg act ttg agc tcc aaa aaa gat tac ctg cat gga gac aat tca gat	192
Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp	
50 55 60	
gtc atc cct aca gac acc atc aag aac aca gtt aat gtc ctg gcg aag	240
Val Ile Pro Thr Asp Thr Ile Lys Asn Thr Val Asn Val Leu Ala Lys	
65 70 75 80	
ttc aaa ggc atc aaa agc ata gaa act ttt gct gtg act atc tgt gag	288
Phe Lys Gly Ile Lys Ser Ile Glu Thr Phe Ala Val Thr Ile Cys Glu	
85 90 95	
cat ttc ctt tct tcc ttc aag cat gtc atc aga gct caa gtc tat gtg	336
His Phe Leu Ser Ser Phe Lys His Val Ile Arg Ala Gln Val Tyr Val	
100 105 110	
gaa gaa gtt cct tgg aag cgt ttt gaa aag aat gga gtt aag cat gtc	384
Glu Glu Val Pro Trp Lys Arg Phe Glu Lys Asn Gly Val Lys His Val	
115 120 125	
cat gca ttt att tat act cct act gga acg cac ttc tgt gag gtt gaa	432
His Ala Phe Ile Tyr Thr Pro Thr Gly Thr His Phe Cys Glu Val Glu	

130 135 140

cag ata agg aat gga cct cca gtc att cat tct gga atc aaa gac cta 480
 Gln Ile Arg Asn Gly Pro Pro Val Ile His Ser Gly Ile Lys Asp Leu
 145 150 155 160

aaa gtc ttg aaa aca acc cag tct ggc ttt gaa gga ttc atc aag gac 528
 Lys Val Leu Lys Thr Thr Gln Ser Gly Phe Glu Gly Phe Ile Lys Asp
 165 170 175

cag ttc acc acc ctc cct gag gtg aag gac cgg tgc ttt gcc acc caa 576
 Gln Phe Thr Thr Leu Pro Glu Val Lys Asp Arg Cys Phe Ala Thr Gln
 180 185 190

gtg tac tgc aaa tgg cgc tac cac cag ggc aga gat gtg gac ttt gag 624
 Val Tyr Cys Lys Trp Arg Tyr His Gln Gly Arg Asp Val Asp Phe Glu
 195 200 205

gcc acc tgg gac act gtt agg agc att gtc ctg cag aaa ttt gct ggg 672
 Ala Thr Trp Asp Thr Val Arg Ser Ile Val Leu Gln Lys Phe Ala Gly
 210 215 220

ccc tat gac aaa ggc gag tac tca ccc tct gtg cag aag acc ctc tat 720
 Pro Tyr Asp Lys Gly Glu Tyr Ser Pro Ser Val Gln Lys Thr Leu Tyr
 225 230 235 240

gat atc cag gtg ctc tcc ctg agc cga gtt cct gag ata gaa gat atg 768
 Asp Ile Gln Val Leu Ser Leu Ser Arg Val Pro Glu Ile Glu Asp Met
 245 250 255

gaa atc agc ctg cca aac att cac tac ttc aat ata gac atg tcc aaa 816
 Glu Ile Ser Leu Pro Asn Ile His Tyr Phe Asn Ile Asp Met Ser Lys
 260 265 270

atg ggt ctg atc aac aag gaa gag gtc ttg ctg cca tta gac aat cca 864
 Met Gly Leu Ile Asn Lys Glu Glu Val Leu Leu Pro Leu Asp Asn Pro
 275 280 285

tat gga aaa att act ggt aca gtc aag agg aag ttg tct tca aga ctg 912
 Tyr Gly Lys Ile Thr Gly Thr Val Lys Arg Lys Leu Ser Ser Arg Leu
 290 295 300

tga 915

305

<210> 2
 <211> 304
 <212> PRT
 <213> Artificial Sequence

<400> 2
 Met Ala His Tyr Arg Asn Asp Tyr Lys Lys Asn Asp Glu Val Glu Phe
 1 5 10 15

Val Arg Thr Gly Tyr Gly Lys Asp Met Ile Lys Val Leu His Ile Gln
 20 25 30

Arg Asp Gly Lys Tyr His Ser Ile Lys Glu Val Ala Thr Ser Val Gln
 35 40 45

Leu Thr Leu Ser Ser Lys Lys Asp Tyr Leu His Gly Asp Asn Ser Asp